# The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment

> **NCT01796288** · PHASE2 · UNKNOWN · sponsor: **Wu Jieping Medical Foundation** · enrollment: 200 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer, Oligometastatic

## Interventions

- **RADIATION:** simultaneous radiotherapy
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01796288
- **Lead sponsor:** Wu Jieping Medical Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-10
- **Primary completion:** 2016-04
- **Final completion:** 2017-10
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2013-02-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01796288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01796288, "The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01796288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*